<SEC-DOCUMENT>0001144204-16-117700.txt : 20160809
<SEC-HEADER>0001144204-16-117700.hdr.sgml : 20160809
<ACCEPTANCE-DATETIME>20160809161546
ACCESSION NUMBER:		0001144204-16-117700
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160803
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160809
DATE AS OF CHANGE:		20160809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161818098

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v446368_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>August 3, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 34%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Delaware</u></b></font></td>
    <td style="width: 33%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>0-9314</u></b></font></td>
    <td style="width: 33%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>83-0221517</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(214) 214-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01. Entry into a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abeona Therapeutics Inc. (&quot;Abeona&quot;
or &ldquo;Company&rdquo;), entered into an agreement (&ldquo;Agreement&rdquo;) with EB Research Partnership (&ldquo;EBRP&rdquo;)
and Epidermolysis Bullosa Medical Research Foundation (&ldquo;EBMRF&rdquo;) to collaborate on gene therapy treatments for epidermolysis
bullosa (&ldquo;EB&rdquo;). The Agreement became effective on the execution of two licensing agreements with The Board of Trustees
of Leland Stanford Junior University (&ldquo;Stanford&rdquo;) described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EBRP and EBMRF have the contractual right
to license from Stanford EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)), and wishes to have Abeona exercise
such rights and enter into a license with Stanford for such technology, and perform preclinical development and perform clinical
trials of a gene therapy treatment for Epidermolysis Bullosa based upon such in-licensed technology. Abeona shall also enter into
a license with Stanford for the AAV-based gene therapy EB-201 (AAV DJ COL7A1) technology, and Abeona shall perform preclinical
development and perform clinical trials of a gene therapy treatment for EB based upon such in-licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Agreement Abeona
will issue to EBRP and EBMRF an aggregate of 750,000 unregistered shares of Abeona Common Stock, $0.01par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 3, 2016 we also entered into
two licensing agreements between us and Stanford to develop EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES))
and EB-201 (AAV DJ COL7A1). And the second agreement to license the invention &ldquo;Gene Therapy for Recessive Dystrophic EB using
Genetically Corrected Autologous Keratinocytes&rdquo;. Under the terms of the licensing agreements, we will pay a upfront licensing
fees in cash, annual license maintenance fees and subject to the achievement of certain milestones, regulatory approval milestone
payments, and royalty payments on annual net sales of the licensed product.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02. Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in Item 1.01 of this Current Report on Form 8-K, as part of the Agreement Abeona will issue
an aggregate of 750,000 unregistered shares of Abeona Common Stock, $0.01 par value, 375,000 each to EBRP and EBMRF. The offer,
sale, and issuance of the shares of Abeona common stock are exempt from registration pursuant to Rule 506 of Regulation D and Section
4(2) of the Securities Act of 1933, as amended. The recipients of securities under the Agreement agreed that day are acquiring
the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate
legends are to be affixed to the securities to be issued in conjunction with the Agreement. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares will be subject to restrictions on selling, transferring or otherwise disposing of such shares. These restrictions shall
lapse with respect to an aggregate 250,000 shares on the first anniversary of the issue date; and with respect to an additional
aggregate 500,000 shares on the second anniversary of the issue date. We have an option to acquire an additional license in the
future for an additional amount shares as set forth in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
8.01.&nbsp;&nbsp;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 9, 2016, we issued a press release
announcing the definitive agreement entitled &ldquo;Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation
to Collaborate on Epidermolysis Bullosa (EB) Treatments&rdquo;. The full text of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and</B> <B>Exhibits. </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt 1.5pt 8pt"><B><U>Exhibit No.</U></B></TD>
    <TD STYLE="padding: 1.5pt 1.5pt 8pt"></TD>
    <TD STYLE="padding: 1.5pt 1.5pt 8pt"><B><U>Description</U></B></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding: 1.5pt">99.1</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">Press release dated August 9, 2016, entitled &ldquo;Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments&rdquo;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>Abeona Therapeutics Inc.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">(Registrant)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Stephen B. Thompson</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid"><P STYLE="margin-top: 0; margin-bottom: 0">Stephen B. Thompson<BR>Vice President Finance</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">Chief Accounting Officer</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">Date:&nbsp;&nbsp;August
9, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Exhibit Number</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated August 9, 2016, entitled &ldquo;Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v446368_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 86px; width: 240px"></TD>
    <TD STYLE="width: 50%"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 54pt; width: 137.85pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics, EB Research Partnership
and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New York, NY and Cleveland, OH &ndash; August 9, 2016 &ndash;
</B>Abeona Therapeutics Inc. (Nasdaq: ABEO)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Collaboration will focus on gene therapy treatments for epidermolysis bullosa (EB)</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>EB-101, an ex vivo gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), demonstrated
promising Phase 1 results </I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Phase 2 clinical trials expected to begin in 3Q2016 for EB-101</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>EB-201 is a pre-clinical candidate targeting a novel, AAV-mediated gene editing and delivery approach to correct gene
mutations in skin cells (keratinocytes)</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc. (Nasdaq: ABEO<FONT STYLE="font-size: 10pt">&nbsp;</FONT>),
a clinical-stage biopharmaceutical company focused on delivering gene and plasma-based therapy for life-threatening rare diseases,<FONT STYLE="background-color: white">
</FONT>EB Research Partnership (EBRP) and EB Research Medical Foundation (EBMRF) announced today a collaboration focusing on gene
therapy treatments for epidermolysis bullosa (EB), a group of devastating rare genetic skin disorders impacting children; characterized
by skin blisters and erosions all over the body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The addition of the EB gene therapy programs to our clinical
pipeline advances our mission of serving those impacted by rare disease. The strong Phase 1 clinical data demonstrate safety and
initial efficacy <FONT STYLE="font-size: 10pt">&nbsp;</FONT> one year post treatment, and support a follow-on Phase 2 trial for
children suffering from EB,&rdquo; said Timothy Miller, PhD., President and CEO of Abeona Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This collaboration builds on our strengths in developing
gene therapies for devastating rare diseases in partnership with patient groups and academic research centers,&rdquo; said Steven
H. Rouhandeh, Executive Chairman of Abeona Therapeutics. &ldquo;We are proud to work with the EB Research Partnership, EB Medical
Research Foundation and Stanford University to accelerate these promising product candidates towards commercialization.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phase 1 clinical trial results for the lead EB program, EB-101
for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), were recently presented at the opening Plenary Session
of the Society for Investigative Dermatology in May 2016. Investigators at Stanford are recruiting patients for a Phase 2 trial
to begin soon. These novel gene therapy products were developed at the Stanford University School of Medicine and are<FONT STYLE="font-size: 10pt">&nbsp;</FONT>
exclusively licensed to Abeona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This collaboration exemplifies the mission of EBRP to
advance commercially sustainable research aimed at treating and ultimately curing epidermolysis bullosa,&rdquo; stated Alexander
Silver, co-founder and Chairman, EBRP. &ldquo;We believe that Abeona can fully realize our mission of progressing research insights
from academia into life-changing treatment solutions for EB patients and their families. This partnership also validates EBRP&rsquo;s
venture philanthropy model, which is important in getting treatments to patients as soon as possible. We are thankful to the team
at Stanford for all their hard work and assistance in forming this partnership.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recessive dystrophic epidermolysis bullosa</B> <B>(RDEB)</B>
is a severe inherited blistering skin disease caused by absence of a protein known as type VII collagen. Patients with RDEB develop
large, severely painful blisters and chronic wounds from minor trauma to their skin and there are currently no FDA approved treatments.
The Phase 1 clinical trial with gene-corrected skin grafts has shown promising wound healing and safety in adult patients with
RDEB. Investigators at Stanford are now recruiting patients for a Phase 2 trial with EB-101 in adolescents age 13 and older to
determine the effect of type VII collagen gene-corrected grafts on wound healing efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Epidermolysis Bullosa (EB)</B>: EB is a group of devastating,
life-threatening genetic skin disorders impacting children that is characterized by skin blisters and erosions all over the body.
One of the most severe forms is recessive dystrophic epidermolysis bullosa (RDEB) characterized by chronic skin blistering, open
and painful wounds, joint contractures, esophageal strictures, pseudosyndactyly, corneal abrasions, and a shortened life span.
Patients with RDEB lack functional type VII collagen owing to mutations in the gene COL7A1 that encodes for C7. C7 is the main
component of anchoring fibrils that attach the dermis to the epidermis. EB patients suffer through intense pain throughout their
lives, with few or no effective treatments available to reduce the severity of their symptoms. Along with the life-threatening
infectious complications associated with this disorder, many individuals will develop an aggressive form of squamous cell carcinoma
(SCC). Abeona&rsquo;s lead EB product, EB-101 (gene-corrected skin grafts), is a gene therapy currently in clinical trials for
the treatment of RDEB patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Abeona: </B><FONT STYLE="color: #26282A; background-color: white">Abeona
Therapeutics Inc. is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening
rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based
gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy
for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene
editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including
SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF&trade; (Salt Diafiltration) ethanol-free
process. For more information, visit </FONT><FONT STYLE="color: #0081F2; background-color: white">www.abeonatherapeutics.com</FONT><FONT STYLE="color: #26282A; background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #26282A; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #26282A; background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #26282A; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About EB Research Partnership (EBRP):</B> EBRP is the largest
501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa, a group of devastating
and life-threatening skin disorders that affect children from birth. EBRP uses a sustainable philanthropic model via venture philanthropy
for all of its research commitments. To learn more, please visit ebresearch.org.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>About
EB Medical Research Foundation (EBMRF<FONT STYLE="color: #555555">): </FONT></B></FONT>The Epidermolysis Bullosa Medical Research
Foundation was founded in 1991 with the mission of funding a cure for EB and is currently headed by The Joseph Family in Los Angeles.
The Foundation is dedicated to raising funds and awareness for critical EB research, as well as providing outreach through the
media and various fundraising programs. To learn more, please visit <FONT STYLE="color: Blue"><U>www.ebkids.org</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26282A; background-color: white"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933,
as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development
and internationalization of our clinical programs, management plans for the Company,our expectation to accelerate our product candidates</I></FONT><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #26282A; background-color: white"><I>
towards commercialization,and general business outlook. These statements are subject to numerous risks and uncertainties, including
but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact
of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals;
the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to
time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.
The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update
them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future
developments or otherwise.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #26282A; background-color: white"><I>&nbsp;</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company and Media Contact:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andre'a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc<BR>
+1 (212)-786-6208<BR>
<FONT STYLE="color: Blue"><U>alucca@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Berni-Silverstein<BR>
Vice President, Investor Relations<BR>
Abeona Therapeutics Inc<BR>
+1 (212)-786-6212<BR>
<FONT STYLE="color: Blue"><U>csilverstein@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EBRP</B><FONT STYLE="font-size: 10pt">&nbsp;</FONT> <B>Company
and Media Contact:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jessica Scheer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EB Research Partnership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (212) 554-1413</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>jessica@ebresearch.org</U></FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 / # 2(  A$! Q$!_\0
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MBGRP7,WKT_S+J<TWRI:=?\CI-2LM-U;29],NS"UK-'Y;(& P.V/0CC'TKC_
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M)V1Q+DG R3Z8''YT75E]INK.;?M^S2F3&,[LJRX]NM,O;*6>YMKJWF6.:#<
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M&CK>>6RC[5# %W[9!EU4[QCY3SG;Z>F:>^N7*W<P^RQ?9HKZ.R+>:=Y+A/F
MQC@N.,]C1R,.=&YSZ"CGT%8,FOSK=,%MHC;K?K8DM*0^XXRV,8QST].:O:W=
MW5EIZS6@B,IGAC_>YQAI%4]/K2Y7=(.96N:'/H*.?05B7.M3I.(+:.VED6T:
MZD<RD(0IV[5(![YY[5'<^(I1$9+:VC(33Q?N)I=ORG.%& >>#D]N*?(PYT;_
M #Z"CGT%<_>>(KB*7R[:R$I2S2[<,Q&0V<*" 0/NGDX'2K$.IW3^(9[5S;):
M+#"R;F(D+/OX]#]RCD8<Z-CGT%'/H*YK0=:O98M-AO523[8LQ257^;Y#_$,
M<CT]*GTCQ!<:E-;%[+RX+J)Y(W#'*[2, Y SD'^'.,4.#0E-,WN?04<^@K,T
M34;S4[2*[GM8H89XEEC*2[B,_P )X'MS[TAO[E/$,EH[6JV@BB9=S$.68N,#
ML?N]*7*[V'S*US4Y]!1SZ"L+3]?FO)K!GMHT@O\ S/)VN2Z[,GYACN >G0X%
M3:]->)-I<-K*L:W%V(Y3N()4(S8!P?[M'([V8<RM=&OSZ"CGT%8+ZW-$)A#
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X0P#17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    @    <@$R  (    4
M    DH=I  0    !    J    -0 "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H36%C:6YT;W-H*0 R,#$T.C Y.C(R(#$Q.C U.C(V
M  .@ 0 #     ?__  "@ @ $     0   3B@ P $     0   &L
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   *R0        !(     0   $@
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MKZCZ8Q' "PVD-;J?;[W%NQV_Z'\M<W1T+ZD47>L[-JN:#(JMR*RP?)I8Y_\
MUQSUX$DG#BHU;;Y;[YP3^[^YP?I^WQ5?_?/U/3Z7I,]#;Z.T>GLC;MCV;-OM
MV;5G]8QNAY.VOJ;ZJ[8FMSGBNP#^0[<U^S_P-?-"24./B'!?%TX?F:.;V^&7
MNUP?I>Y\OUXGZ-Z3TSZMX>2U^+D,R,HR*B^UCW#3W>DQFWW;?Y&];J^54D[+
M[O%^MOB_K=EG+^QP?J.'@_J=WZJ27RJDHV9^JDE\JI)*?JI)?*J22GZJ27RJ
MDDI^JDE\JI)*?JI)?*J22G__V?_M$^Y0:&]T;W-H;W @,RXP #A"24T$)0
M    $                      X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 4@
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ !(     0 ! $@
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300        "   X0DE-! (       0     .$))300P       " 0$X
M0DE-!"T       8  0    $X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #/0    8              &L
M  $X    ! !L &\ 9P!O     0                         !
M      $X    :P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    :P    !29VAT;&]N9P   3@    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &L
M4F=H=&QO;F<   $X     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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MYRG_ (1 S^H9G4+S=EOWN$[6CZ# ?S:6_FM_E?GI^#DY9#<CPP'7][^Z\?\
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MF?TC_O/5<OA&'%#&/T!^/Z3>;]??J>YP:WJE)<X@ #=J28'YJM=3^M'0.DY
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300&       '  @! 0 ! 0#_X0ZQ:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @
M0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@
M(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M
M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;7 Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*$UA8VEN=&]S:"DB('AM
M<#I#<F5A=&5$871E/2(R,#$T+3 Y+3(R5#$Q.C S.C0X+3 W.C P(B!X;7 Z
M36]D:69Y1&%T93TB,C Q-"TP.2TR,E0Q,3HP-3HR-BTP-SHP,"(@>&UP.DUE
M=&%D871A1&%T93TB,C Q-"TP.2TR,E0Q,3HP-3HR-BTP-SHP,"(@9&,Z9F]R
M;6%T/2)I;6%G92]J<&5G(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S(B!P:&]T
M;W-H;W Z24-#4')O9FEL93TB1&ES<&QA>2(@>&UP34TZ26YS=&%N8V5)1#TB
M>&UP+FEI9#HP-#@P,3$W-# W,C V.#$Q.# X,T)$,#E!.4(W-S9#."(@>&UP
M34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HP,S@P,3$W-# W,C V.#$Q.# X,T)$
M,#E!.4(W-S9#."(@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)X;7 N9&ED
M.C S.# Q,3<T,#<R,#8X,3$X,#@S0D0P.4$Y0C<W-D,X(CX@/'!H;W1O<VAO
M<#I$;V-U;65N=$%N8V5S=&]R<SX@/')D9CI"86<^(#QR9&8Z;&D^>&UP+F1I
M9#HX0CA",S,S1#0W,C V.#$Q.# X,SA",S8T.$(V1#,R-#PO<F1F.FQI/B \
M+W)D9CI"86<^(#PO<&AO=&]S:&]P.D1O8W5M96YT06YC97-T;W)S/B \>&UP
M34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C
M<F5A=&5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C S.# Q,3<T,#<R
M,#8X,3$X,#@S0D0P.4$Y0C<W-D,X(B!S=$5V=#IW:&5N/2(R,#$T+3 Y+3(R
M5#$Q.C S.C0X+3 W.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0
M:&]T;W-H;W @0U,V("A-86-I;G1O<V@I(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E<G,](F9R;VT@:6UA9V4O
M<&YG('1O(&EM86=E+VIP96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A
M=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C T.# Q,3<T,#<R,#8X
M,3$X,#@S0D0P.4$Y0C<W-D,X(B!S=$5V=#IW:&5N/2(R,#$T+3 Y+3(R5#$Q
M.C U.C(V+3 W.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W @0U,V("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO
M<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B \+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" \/WAP86-K970@96YD/2)W(C\^_^(,M$E#0U]04D]&24Q%  $!   ,I&%P
M<&P"$   ;6YT<E)'0B!865H@!]X  P 9 !$ ,P D86-S<$%04$P
M                         /;6  $     TRUA<'!L
M                                               19&5S8P   5
M  !B9'-C;0   ;0   &,8W!R=    T     D=W1P=    V0    4<EA96@
M W@    49UA96@   XP    48EA96@   Z     4<E120P   [0   @,86%R
M9P  "\     @=F-G=   "^     P;F1I;@  #!     ^8VAA9   #%     L
M;6UO9   #'P    H8E120P   [0   @,9U120P   [0   @,86%B9P  "\
M   @86%G9P  "\     @9&5S8P         (1&ES<&QA>0
M
M                                 &UL=6,         '@    QS:U-+
M    %    7AC8453    %    7AH94E,    %    7AP=$)2    %    7AI
M=$E4    %    7AH=4A5    %    7AU:U5!    %    7AK;TM2    %
M 7AN8DY/    %    7AC<T-:    %    7AZ:%17    %    7AD941%
M%    7AR;U)/    %    7AS=E-%    %    7AZ:$-.    %    7AJ84I0
M    %    7AA<@      %    7AE;$=2    %    7AP=%!4    %    7AN
M;$Y,    %    7AF<D92    %    7AE<T53    %    7AT:%1(    %
M 7AT<E12    %    7AF:49)    %    7AH<DA2    %    7AP;%!,
M%    7AR=5)5    %    7AE;E53    %    7AD841+    %    7@ 00!C
M &4 <@ @ $< ,@ S #4 2'1E>'0     0V]P>7)I9VAT($%P<&QE+"!);F,N
M+" R,#$T %A96B        #SV  !     18(6%E:(        '27   \,P
M H%865H@        77X  +$K   5 5A96B         DP0  $J$  +NK8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ V #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *, J "M +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M__]P87)A       #
M F9F  #RIP  #5D  !/0   *#G9C9W0          0 !          $    !
M          $    !          $  &YD:6X         -@  I,   %8   !-
M    G(   "6    1@   4$   %1   (S,P ",S,  C,S          !S9C,R
M       !"[<   66___S5P  !RD  /W7___[M____:8   /:  # ]FUM;V0
M       $<@   1,3$'?ORECZ                      #_[@ A061O8F4
M9$     ! P 0 P(#!@               /_; (0  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,#
M P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@ :P$X P$1  (1 0,1 ?_$
M /   0 " @(# 0$            )"@<(!08#! L! @$!   & P$
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M1-^ZS<DQ\;B'LQ1[0CQS2Z#7EQT&_MF,C0
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MH,-^+"U^+!T; M+B!IH=X7XL+1DC>7MLLJ)=4"[5P-;=7 W6:O!J'KV[_;M
MNNMH#?75P5UM*V74MZBY@<H.R7X3<1?>)0[;G'L;IY+_ +:_<V;*$"LUS'5[
MC;$?[I2#$O&]@;5:5I4:E;DZ@(U:BW5"3P+K;!;1 _ OBM;ZV5M'\75]P#[K
M1 J6UK06VVZP*T42EX?79?>%>A2JN)MK8<-CE3M1::M+NO8_?;84]-I#G\)D
MJ[VDYX/X3<C_ '9L[<6$_*WZ$O\ <$J+4 E^5$U2@2B#8'6^^X+Q:(#<'=<!
M2FK@;*67%[[;_9MI;0*VMOL>*U#_ ): UK;0"E>M-(B*2@G$0$TCI*4!$E3
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MCISU!,5XA_YD8?:05U"<Z+AF[VFQ/D'.++W#L@B8R-%FY(\[N;C!>,GXWO\
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MM<N^E*[<]N(%= 0 :G/+,[JT/73?@HT@$@8FIV&M-_HQ,H96)INRVY^K$-
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M?Z"-RG#2.:*,/*=F[N_7/IYU@D6H&GR.*_6BI*I]:#S[3&E-$?C3TLIX?6P
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5,<B.:J.1%^/"?)$^2(GX(G_$'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
